Denali Therapeutics Inc
Denali Therapeutics Inc (DNLI) Expected Move
DNLI expected move through Nov 20, 2026 is 38.0%, with 4 days to expiration. The implied range is $11.61 to $25.87, based on the previous trading day's options prices.
Read more
Tracking the DNLI expected move helps you see how far Denali Therapeutics Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Denali Therapeutics Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the DNLI expected move for this week's options, in real time.
The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For DNLI, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The DNLI expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Denali Therapeutics Inc is unlikely to go.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus.
Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the DNLI expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Denali Therapeutics Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about DNLI.
DNLI Price
Drag chart to pan. Drag axes to zoom.
| Expiration | DTE | Expected move (USD) | Expected move (%) | Upper price | Lower price |
|---|---|---|---|---|---|
| Nov 20, 2026 | 4 | $7.13 | 38.0% | $25.87 | $11.61 |
| Dec 18, 2026 | 32 | $5.96 | 31.8% | $24.70 | $12.78 |
| Mar 19, 2027 | 123 | $6.36 | 34.0% | $25.10 | $12.38 |
| Jun 17, 2027 | 213 | $8.93 | 47.6% | $27.67 | $9.81 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →